Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.6K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

263
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
263
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoxia-driven T cell-macrophage-stromal cross-talk sustains fibrosis in preclinical models of cutaneous chronic graft-versus-host disease.

Science translational medicine·2026
Same author

T cell-macrophage crosstalk in GVHD and cancer immunotherapy.

Cell investigation·2026
Same author

Vancomycin-Tacrolimus Combination-Related Acute Kidney Injury Risk in Posthematopoietic Stem Cell Transplant Patients.

Transplantation and cellular therapy·2026
Same author

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Blood advances·2026
Same author

Transportability to the European Population of Efficacy of Belumosudil as Compared With Physician's Choice of Best Available Therapy for the Treatment of Chronic Graft Versus Host Disease.

Transplantation and cellular therapy·2026
Same author

Dysbiosis and gastrointestinal GVHD: to treat or not to treat.

Blood·2026

Related Experiment Video

Updated: May 12, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.1K

SOHO State of the Art Updates and Next Questions | Transplanting Hope: Managing Relapsed/Refractory AML.

Christopher Ronald Funk1, Edmund K Waller1

  • 1Department of Hematology & Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.

Clinical Lymphoma, Myeloma & Leukemia
|May 8, 2025
PubMed
Summary
This summary is machine-generated.

Acute myeloid leukemia (AML) patients with high leukemia burden face poor outcomes after stem cell transplant. Novel graft engineering and bridging therapies show promise for improving remission and survival rates.

Keywords:
Acute myeloid leukemiaAllogeneic transplantationConditioning regimensGraft engineeringGraft-versus-leukemia

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.1K

Related Experiment Videos

Last Updated: May 12, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.1K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Acute myeloid leukemia (AML) is a complex blood cancer with high relapse rates, especially after induction therapy.
  • Allogeneic hematopoietic cell transplantation (allo-HCT) offers a graft-versus-leukemia (GVL) effect but has limited success in patients with high leukemia burden.
  • Leukemia burden at transplant and minimal residual disease (MRD) positivity are critical predictors of poor survival outcomes.

Purpose of the Study:

  • To review emerging strategies for improving outcomes in patients with persistent or relapsed AML undergoing allo-HCT.
  • To highlight the role of aggressive bridging therapies and innovative graft engineering in managing high leukemic burden.

Main Methods:

  • Review of current literature and emerging strategies for AML treatment post-induction therapy.
  • Focus on bridging therapies including chemotherapy, hypomethylating agents, targeted inhibitors, and sequential induction-conditioning (e.g., FLAMSA).
  • Evaluation of novel graft engineering techniques, such as ORCA-T, for optimizing T-cell ratios in stem cell grafts.

Main Results:

  • High leukemia burden and MRD positivity significantly reduce survival post-allo-HCT.
  • Aggressive bridging therapies and tailored conditioning regimens are being investigated to reduce disease burden before transplant.
  • Graft engineering strategies, like ORCA-T, aim to enhance the GVL effect while mitigating graft-versus-host disease.

Conclusions:

  • Improved strategies are urgently needed to overcome high relapse rates in AML patients undergoing allo-HCT.
  • Innovative approaches including aggressive pre-transplant therapies and advanced graft engineering hold significant promise for improving patient outcomes.
  • Further clinical evaluation, including phase III trials for methods like ORCA-T, is crucial to establish their efficacy in treating relapsed/persistent AML.